Polarean Imaging plc (AIM:POLX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
0.9250
+0.0018 (0.19%)
Aug 15, 2025, 4:35 PM GMT+1

Polarean Imaging Company Description

Polarean Imaging plc operates as a drug-device manufacturer and service provider for noble gas hyperpolariser devices in Canada, the United Kingdom, and the United States.

The company engages in the research, development, and commercialization of novel imaging solutions with a non-invasive and radiation-free functional imaging platform.

It also offers XENOVIEW, a hyperpolarized contrast agent indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older; chest coil; Polarean 9820 Xenon hyperpolarizer that is designed to deliver up to 3 litres of hyperpolarized 129Xe per hour; and Polarean 2881 polarization measurement station, which provides a calibrated measurement of the polarization of hyperpolarized gas within the dose delivery inhalation bag.

Polarean Imaging plc was incorporated in 2016 and is based in London, the United Kingdom.

Polarean Imaging plc
Country United Kingdom
Founded 2016
Industry Medical Devices
Sector Healthcare
Employees 26
CEO Christopher Von Jako

Contact Details

Address:
27-28 Eastcastle Street
London, W1W 8DH
United Kingdom
Website polarean.com

Stock Details

Ticker Symbol POLX
Exchange London Stock Exchange AIM
Fiscal Year January - December
Reporting Currency USD
ISIN Number GB00BF3DT583
SIC Code 3821

Key Executives

Name Position
Christopher Von Jako Chief Executive Officer
Charles Osborne Chief Financial Officer
Neil Wadehra Chief Operating Officer